Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Various driver gene mutations have been identified in lung cancer. Among them, human
epidermal growth factor 2 (HER2) was identified in about approximately 2% of non-small cell
lung cancers.Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2
receptors. This study is designed to evaluate the efficacy and safety of Pyrotinib in
patients with HER2 positive advanced Non-small cell lung cancer.